ASLAN Pharmaceuticals Ltd (亞獅康) yesterday announced that US-based Array BioPharma Inc has granted the company full global rights to develop, manufacture and commercialize varlitinib, an inhibitor that helps control tumor growth which is being developed for a variety of cancer types.
The new agreement replaces a pact signed in 2011 that granted ASLAN the rights to develop varlitinib through proof of concept, as well as seeking a partner to complete phase III clinical trials and commercialization approval processes, the Singaporean company said.
Vartlitinib has demonstrated strong efficacy in the studies since 2011 in biliary tract, gastric, breast and colorectal cancer, ASLAN chief executive officer Carl Firth said in a statement.
“We want to take the drug to the market and commercialize it ourselves in certain regions, which was not contemplated under the original agreement,” Firth said.
The new agreement allows the company to retain much more downstream value from the firm’s commercial and partnering activities, he said.
Array is eligible to receive 50 percent of all varlitinib revenue, which was unchanged from the previous agreement, an investor relations officer at ASLAN said, adding that the company now has the freedom to decide whether to enlist partners or pursue commercialization in-house on a market-by-market basis.
Under the new agreement, ASLAN will make an upfront payment of US$12 million to Array on signature and a payment of up to US$12 million within the next year.
The company has also agreed to pay up to US$30 million in development and US$75 million in commercial milestones for varlitinib, as well as royalties as a percentage in the low double digits of net sales of the drug.
The US Food and Drug Administration offered the orphan drug designation to varlitinib as a treatment for cholangiocarcinoma in 2015 and gastric cancer in 2016, the company said.
Shares in ASLAN yesterday fell 0.15 percent to close at NT$33.65 on the Taipei Exchange.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last